Netherton Syndrome Clinical Trial
Official title:
Defining the Skin and Blood Biomarkers of Ichthyosis
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis. Hypothesis: We predict that the biomarkers correlating with disease activity in Netherton syndrome will be different than the biomarkers found to correlate with the lamellar and other ichthyosis phenotype.
Objectives: 1. To define a panel of skin and blood biomarkers associated with disease activity and pruritus in Netherton syndrome, lamellar ichthyosis, and other ichthyosis subtypes. 2. To determine if blood samples can serve as surrogates for skin immune activation and will correlate with disease severity. 3. To determine FLG, SPINK5, TGM1, or other mutation via buccal/saliva samples in ichthyosis subjects 4. To determine differences in alterations of epidermal lipids and proteins in the outer stratum corneum of epidermis collected from tape strips in patients with ichthyosis compared to the general population. There will also be a difference detected in epidermal lipids from blood samples. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05979831 -
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT00208026 -
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT05583669 -
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01428297 -
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
|
Phase 1 | |
| Recruiting |
NCT05856526 -
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05789056 -
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05521438 -
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT05388903 -
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06137157 -
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
|
Phase 1 | |
| Not yet recruiting |
NCT05902663 -
Natural History of Netherton Syndrome
|
||
| Recruiting |
NCT04244006 -
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT02113904 -
Clinical Trial Using Humira in Netherton Syndrome
|
Phase 2 | |
| Recruiting |
NCT05211830 -
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
| Recruiting |
NCT01545323 -
Gene Therapy for Netherton Syndrome
|
Phase 1 | |
| Recruiting |
NCT02081313 -
Natural History and Biological Study of Netherton Syndrome
|
N/A |